Teva’s Copaxone Shows Continued Efficacy In Long-Term Trial; Study Extended To 15 Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva reported no cases of immune-mediated adverse events in a 10-year study of its multiple sclerosis therapy glatiramer.